2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6310 Real-world outcomes of patients treated with talquetamab for relapsed or refractory multiple myeloma: A retrospective observational study in US academic centers

Carlyn Rose Tan, MD, Andriy Derkach, PhD2, Natalie Solberg, MPH3, Natasha Harpalani, MD4, Mansi Ramesh Shah, MD5, Nishi Shah, MD, MPH6, Nisha Joseph, MD7, Binod Dhakal, MD, MS8, Jeffrey A. Zonder, MD9, Craig Cole I, MD10, Yitian Zhang11, Ming-Hui Tai12, Ibrahim Saber, MD13, Jessica Fowler, PhD14, Shuchita Kaila, PhD15, Saad Z. Usmani, MD16
1 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, New Jersey, United States
5 Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, New Jersey, United States
6 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
7 Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
8 Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States
10 Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, United States
11 Johnson & Johnson, Horsham, Pennsylvania, United States
12 Johnson & Johnson, Horsham, Pennsylvania, United States
13 Johnson & Johnson, Horsham, Pennsylvania, United States
14 Johnson & Johnson, Horsham, Pennsylvania, United States
15 Johnson & Johnson, Horsham, Pennsylvania, United States
16 Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States

Introduction: Talquetamab is a first-in-class GPRC5D-targeted bispecific antibody approved for patients (pts) with relapsed or refractory multiple myeloma (RRMM) who have received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody, based on results from the phase 1/2 MonumenTAL-1 trial. However, real-world data for pts receiving talquetamab with long-term follow-up outside of clinical trials remains limited. Here, we evaluated the effectiveness and safety of talquetamab in pts with RRMM in a real-world setting.

Methods: This retrospective observational study included pts aged ≥18 years with RRMM who received ≥1 dose of talquetamab between August 2023 and July 2026 at Memorial Sloan Kettering Cancer Center and other US partner centers (Emory Winship Cancer Institute, Rutgers Cancer Institute, Karmanos Cancer Institute, and Medical College of Wisconsin). Pt-level data were abstracted by each center using standardized case report forms and uploaded to a Research Electronic Data Capture (REDCap) Database. Due to the original design of the study, high-risk cytogenetic abnormalities evaluated included 1q+, t(4;14), t(14;16), t(14;20), and del(17p). Descriptive statistics were used to summarize all study variables. Time-to-event outcomes were assessed using Kaplan-Meier analysis.

Results: Among the 118 pts analyzed, median age was 66 years (range, 27-86), and 51% were female. In pts with available data, 56% were Caucasian, 27% were African American, and 8% were Asian; race was reported as other or unknown in 13 pts. Additionally, 21% of pts had an Eastern Cooperative Oncology Group performance status score ≥2, 33% had International Staging System stage III disease, 84% had high-risk cytogenetics, and 40% had extramedullary disease. Median number of prior lines of therapy was 6 (range, 2-17), 61% of pts had known prior B-cell maturation antigen therapy exposure, and 19 pts received talquetamab as bridging or holding therapy. Talquetamab dosing frequency was primarily every 2 weeks (59%) or weekly (20%). Two (2%) pts received monthly talquetamab dosing and 22 (19%) pts received “other” dosing (including stopped or sporadic dosing). The median follow-up was 13 months (range, 0-33).

Excluding pts who used talquetamab as bridging or holding therapy, 86 of 99 pts were evaluable for response. The overall response rate was 66%, including 42% with very good partial response and 8% with complete response; median time to best response was 1.1 months (range, 0.3-15.6). The median progression-free survival (PFS) was 8.4 months (95% confidence interval [CI], 5.6-13.6) and median overall survival (OS) was 18.8 months (95% CI, 13.4-24.5); estimated 12-month PFS and OS rates were 41.3% and 64.9%, respectively.

Following the first full dose of talquetamab, 10.2% of pts had cytokine release syndrome (CRS; 10 of 12 events were grade 1, with only 1 event with grade 2 and 1 event with grade 3) and 3.4% had immune effector cell–associated neurotoxicity syndrome (ICANS; 3 events with grade 1 and 1 event with grade 2); 11.9% of pts had recurrent CRS. Other adverse events of interest included dysgeusia in 65.3% of pts (23.7% grade 1 and 29.7% grade 2 for pts with available grade) and nail-related changes in 24.6% of pts (15.3% grade 1 and 5.1% grade 2 for pts with available grade); 2 pts had ataxia (unknown grade). The incidence of infections was 56%, and, among all 118 pts, 28.8% had grade 3/4 at first infection. A total of 57 (48%) pts received intravenous immunoglobulin (IVIG).

Conclusions: In this multi-center real-world cohort of pts with RRMM who were heavily pretreated and frequently had high cytogenetic risk, talquetamab demonstrated clinically meaningful effectiveness. Safety findings were consistent with the known talquetamab profile, with mostly low-grade CRS and ICANS and frequent but low-grade dysgeusia and nail-related adverse events. These results support talquetamab as an effective treatment for pts with RRMM, including pts with high risk.

 

Carlyn Rose Tan, MD: Sanofi - Research Funding; Janssen/Johnson & Johnson - Research Funding; Sanofi - Consultancy (Includes expert testimony); Janssen/Johnson & Johnson - Consultancy (Includes expert testimony)